Open AccessIn vivo magnetic resonance imaging of glucose – initial experience
Author(s) -
AlloucheAr Hyla,
Wade Trevor,
Waldner Lanette Friesen,
Miller Valenti.,
Gomori J. Moshe,
KatzBrull Rachel,
McKenzie Charles A.
Publication year - 2012
Publication title -
contrast media & molecular imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.714
H-Index - 50
eISSN - 1555-4317
pISSN - 1555-4309
DOI - 10.1002/cmmi.1497
Subject(s) - hyperpolarization (physics) , positron emission tomography , in vivo , magnetic resonance imaging , chemistry , nuclear magnetic resonance , nuclear medicine , preclinical imaging , medicine , radiology , nuclear magnetic resonance spectroscopy , physics , microbiology and biotechnology , organic chemistry , biology
A new noninvasive, nonradioactive approach for glucose imaging using spin hyperpolarization technology and stable isotope labeling is presented. A glucose analog labeled with 13 C at all six positions increased the overall hyperpolarized imaging signal; deuteration at all seven directly bonded proton positions prolonged the spin–lattice relaxation time. High‐bandwidth 13 C imaging overcame the large glucose carbon chemical shift dispersion. Hyperpolarized glucose images in the live rat showed time‐dependent organ distribution patterns. At 8 s after the start of bolus injection, the inferior vena cava was demonstrated at angiographic quality. Distribution of hyperpolarized glucose in the kidneys, vasculature, and heart was demonstrated at 12 and 20 s. The heart‐to‐vasculature intensity ratio at 20 s suggests myocardial uptake. Cancer imaging, currently performed with 18 F‐deoxyglucose positron emission tomography (FDG‐PET), warrants further investigation, and glucose imaging could be useful in a vast range of clinical conditions and research fields where the radiation associated with the FDG‐PET examination limits its use. Copyright © 2012 John Wiley & Sons, Ltd.